Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.52 |
| ▸ | ARHGDIA | P52565 | 4/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746411 | 1.00 | ROCK2 (0.52) | ROCK2ROCK1ARHGDIACHRNA7CYP3A4 | |
| SCHEMBL747065 | 0.89 | ROCK2 (0.58) | ROCK2ROCK1ARHGDIACHRNA7CYP3A4 | |
| SCHEMBL747066 | 0.89 | ROCK2 (0.58) | ROCK2ROCK1ARHGDIACHRNA7CYP3A4 | |
| SCHEMBL745267 | 0.86 | CHRNA7 (0.48) | CHRNA7MTORKCNH2 | |
| SCHEMBL745268 | 0.86 | CHRNA7 (0.48) | CHRNA7MTORKCNH2 | |
| SCHEMBL5413381 | 0.85 | ROCK2 (0.67) | ROCK2ROCK1ARHGDIACYP3A4CCR2 | |
| Hydrochloric Acid SCHEMBL746659 | 0.85 | CHRNA7 (0.48) | CHRNA7MTORKCNH2 | |
| Hydrochloric Acid SCHEMBL746658 | 0.85 | CHRNA7 (0.48) | CHRNA7MTORKCNH2 | |
| SCHEMBL743914 | 0.83 | KCNH2 (0.47) | ROCK2ROCK1ARHGDIACHRNA7CYP3A4 | |
| SCHEMBL743913 | 0.83 | KCNH2 (0.47) | ROCK2ROCK1ARHGDIACHRNA7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2011090669-A1 | METHODS FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2011-07-28 | — | — | WO | claimed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | claimed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2018380-A2 | CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | Abbott Laboratories (US) | 2009-01-28 | — | — | EP | claimed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | claimed |
| WO-2007137030-A2 | CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2007-11-29 | — | — | WO | claimed |
| US-8940762-B2 | Methods for treating pain | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | ROCK2 3093/4885ROCK1 4137/4885ARHGDIA 3491/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | ROCK2 3093/4885ROCK1 4137/4885ARHGDIA 3491/4885 |
| US-20110178121-A1 | Methods for Treating Pain | CHRNA7, CHRNA3, CHRNA5 | ROCK2 1434/4885ROCK1 1446/4885ARHGDIA 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.